Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,160.65",
    "chg": -9.25,
    "chgp": "-0.79%",
    "dir": -1,
    "prev_price": "1,169.90",
    "mcapval": "96,489.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Aug 04, 03:30 PM",
    "curr_time": "23:57 PM",
    "last_traded_at": "Aug 04, 03:30 PM IST",
    "bse_nse_vol": "22.1 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 04, 2026",
    "traded_date_str": "2026 08 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-amid-mixed-market-signals-4134891",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/DrReddysLaborat_technicaldot_4134891.png",
        "date": "2026-08-04 08:06:45",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest daily gain of 1.94%, the pharmaceutical giant’s broader technical signals present a mixed picture, with key oscillators and moving averages offering contrasting insights into its near-term trajectory."
      },
      {
        "title": "P/E at 29.79 vs Industry's 37.19: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-4133116",
        "imagepath": "",
        "date": "2026-08-03 09:20:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 29.79, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 37.19. This discount suggests the market is pricing in either slower growth prospects or elevated risks relative to peers. The mid-cap stock’s market capitalisation stands at ₹97,081.14 crores, positioning it well within the sector but not among the largest players. The valuation gap raises the question of whether the discount reflects a value opportunity or a justified caution — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" cla..."
      },
      {
        "title": "P/E at 29.64 vs Industry's 37.11: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-mixed-market-performance-and-nifty-50-membership-significance-4129736",
        "imagepath": "",
        "date": "2026-07-31 09:21:17",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premium</strong></p>\n                <p>The stock’s P/E ratio of 29.64 stands well below the industry average of 37.11, indicating that <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> is trading at a roughly 20% discount relative to its sector peers. This valuation gap may reflect investor concerns about recent earnings growth or broader market sentiment towards the company’s prospects. The sector’s elevated P/E suggests that investors are willing to pay a premium for growth or stability in other pharmaceutical companies, whereas <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> is viewed mor..."
      },
      {
        "title": "P/E at 29.6 vs Industry's 37.2: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-sell-downgrade-amidst-challenging-market-performance-4128139",
        "imagepath": "",
        "date": "2026-07-30 09:21:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The stock’s P/E ratio of 29.61 represents a discount of approximately 20.4% relative to the sector average of 37.19. This valuation gap suggests that the market is pricing in either a more cautious outlook on <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> or recognising sector-wide premium valuations that the company does not command. Such a discount can reflect concerns over growth prospects, profitability, or risk factors specific to the company. However, it also raises the question of whether the stock is undervalued relative to its peers — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"..."
      },
      {
        "title": "P/E at 29.42 vs Industry's 36.78: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-headwinds-amidst-nifty-50-membership-and-market-pressures-4125415",
        "imagepath": "",
        "date": "2026-07-29 09:21:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 29.42, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 36.78. This valuation gap suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline prospects, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be viewed more cautiously. This discount could be a function of recent earnings volatility or competiti..."
      },
      {
        "title": "P/E at 29.8 vs Industry's 36.8: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-prolonged-underperformance-in-nifty-50-4123772",
        "imagepath": "",
        "date": "2026-07-28 09:20:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 29.81, which is approximately 19% lower than the Pharmaceuticals & Biotechnology industry average of 36.83. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally robust earnings growth, the valuation gap invites scrutiny — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s lower multiple could reflect concerns about recent operational performance or competitive pressures. <a href=\"h..."
      },
      {
        "title": "P/E at 29.86 vs Industry's 36.38: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-amidst-nifty-50-membership-4122028",
        "imagepath": "",
        "date": "2026-07-27 09:20:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p>The stock’s P/E ratio of 29.86 stands in contrast to the industry average of 36.38, signalling a valuation discount of nearly 18%. This lower multiple could reflect market concerns about growth prospects or recent performance challenges. In the context of a sector where valuations remain elevated, <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears more attractively priced on earnings basis. However, this discount also invites scrutiny on whether it is justified by fundamentals or a symptom of broader investor caution. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys La..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Falls 4.81%: 5 Key Factors Behind the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-falls-481-5-key-factors-behind-the-weekly-decline-4120701",
        "imagepath": "",
        "date": "2026-07-25 16:07:43",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>20 Jul:</strong> Stock opens at Rs.1,223.30, up 1.03% despite flat Sensex</p>\n                    <p><strong>22 Jul:</strong> Q1 FY27 results reveal margin pressures and revenue decline</p>\n                    <p><strong>23 Jul:</strong> Stock hits 52-week low of Rs.1,080.05 with significant gap down</p>\n                    <p><strong>24 Jul:</strong> Technical indicators signal mildly bearish momentum amid continued price pressure</p>\n                    <p><strong>24 Jul:</strong> Week closes at Rs.1,152.60, down 4.81% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-4120286",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/DrReddysLaborat_mojoScore_4120286.png",
        "date": "2026-07-25 10:10:04",
        "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      }
    ],
    "total": 635,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "01-Aug-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015- Press Release",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 Of SEBI (LODR) Regulation 2015",
      "datetime": "29-Jul-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "29-Jul-2026",
      "details": "Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-08-04 08:06:45

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest daily gain of 1.94%, the pharmaceutical giant’s broader technical signals present a mixed picture, with key oscillators and moving averages offering contrasting insights into its near-term trajectory.

Read full news article

P/E at 29.79 vs Industry's 37.19: What the Data Shows for Dr Reddys Laboratories Ltd

2026-08-03 09:20:47

Valuation Picture: Discount to Industry P/E

Dr Reddys Laboratories Ltd trades at a P/E multiple of 29.79, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 37.19. This discount suggests the market is pricing in either slower growth prospects or elevated risks relative to peers. The mid-cap stock’s market capitalisation stands at ₹97,081.14 crores, positioning it well within the sector but not among the largest players. The valuation gap raises the question of whether the discount reflects a value opportunity or a justified caution — Read full news article

P/E at 29.64 vs Industry's 37.11: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-31 09:21:17

Valuation Picture: Discount Amidst Sector Premium

The stock’s P/E ratio of 29.64 stands well below the industry average of 37.11, indicating that Dr Reddys Laboratories Ltd is trading at a roughly 20% discount relative to its sector peers. This valuation gap may reflect investor concerns about recent earnings growth or broader market sentiment towards the company’s prospects. The sector’s elevated P/E suggests that investors are willing to pay a premium for growth or stability in other pharmaceutical companies, whereas Dr Reddys Laboratories Ltd is viewed mor...

Read full news article

P/E at 29.6 vs Industry's 37.2: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-30 09:21:29

Valuation Picture: Discount to Industry P/E

The stock’s P/E ratio of 29.61 represents a discount of approximately 20.4% relative to the sector average of 37.19. This valuation gap suggests that the market is pricing in either a more cautious outlook on Dr Reddys Laboratories Ltd or recognising sector-wide premium valuations that the company does not command. Such a discount can reflect concerns over growth prospects, profitability, or risk factors specific to the company. However, it also raises the question of whether the stock is undervalued relative to its peers — Read full news article

P/E at 29.42 vs Industry's 36.78: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-29 09:21:02

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 29.42, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 36.78. This valuation gap suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline prospects, but Dr Reddys Laboratories Ltd appears to be viewed more cautiously. This discount could be a function of recent earnings volatility or competiti...

Read full news article

P/E at 29.8 vs Industry's 36.8: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-28 09:20:46

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 29.81, which is approximately 19% lower than the Pharmaceuticals & Biotechnology industry average of 36.83. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally robust earnings growth, the valuation gap invites scrutiny — Dr Reddys Laboratories Ltd’s lower multiple could reflect concerns about recent operational performance or competitive pressures. Read full news article

P/E at 29.86 vs Industry's 36.38: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-27 09:20:52

Valuation Picture: Discount Amid Sector Premiums

The stock’s P/E ratio of 29.86 stands in contrast to the industry average of 36.38, signalling a valuation discount of nearly 18%. This lower multiple could reflect market concerns about growth prospects or recent performance challenges. In the context of a sector where valuations remain elevated, Dr Reddys Laboratories Ltd appears more attractively priced on earnings basis. However, this discount also invites scrutiny on whether it is justified by fundamentals or a symptom of broader investor caution. Dr Reddys La...

Read full news article

Dr Reddys Laboratories Ltd Falls 4.81%: 5 Key Factors Behind the Weekly Decline

2026-07-25 16:07:43

Key Events This Week

20 Jul: Stock opens at Rs.1,223.30, up 1.03% despite flat Sensex

22 Jul: Q1 FY27 results reveal margin pressures and revenue decline

23 Jul: Stock hits 52-week low of Rs.1,080.05 with significant gap down

24 Jul: Technical indicators signal mildly bearish momentum amid continued price pressure

24 Jul: Week closes at Rs.1,152.60, down 4.81% for the week

Week OpenRead full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-07-25 10:10:04

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

View All News